Health‐related quality of life · people with dementia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · people with dementia
The review found no eligible studies for this question.
1 finding from 1 review
Activities of daily living · people with dementia
The review found no eligible studies for this question.
1 finding from 1 review
Pain perception according to the Pain VAS scale 0‐10 · patients with chronic LBP or soft tissue pain
1 finding from 1 review
Open reduction and fixation vs Closed (conservative) management (no active intervention other than soft diet, analgesics or antibiotics; or intermaxillary/maxillary-mandibular fixation with rigid or elastic traction)
Outcome not reported · Adults, over 18 years of age, with unilateral or bilateral fractures of the mandibular condyles
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Disimpaction · management of impacted food bolus in the oesophagus
Diazepam and glucagon showed no clear difference in disimpaction compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · NSTI
It is very uncertain whether moxifloxacin changes mortality compared with amoxicillin‐clavulanate (very low certainty).
1 finding from 1 review
SAEs · NSTI
Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
1 finding from 1 review
Survival time · NSTI
1 finding from 1 review
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · NSTI
It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).
1 finding from 1 review
Survival time · NSTI
1 finding from 1 review
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · NSTI
It is very uncertain whether AB103 changes mortality compared with placebo (very low certainty).
1 finding from 1 review
SAEs · NSTI
It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).
1 finding from 1 review
Survival time · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Assessment of long‐term morbidity · NSTI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · NSTI
Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
OS · adults with Hodgkin's lymphoma
1 finding from 1 review
QoL · adults with Hodgkin's lymphoma
1 finding from 1 review